Pharmacology for the Primary Care Provider: Study Guide
(2025/2026 Syllabus)
Disclaimer: This guide is a supplement to, not a replacement for, the textbook and
official course materials. Drug choices and dosages must be verified with current,
authoritative sources before clinical application.
Module 1: Foundations of Pharmacology & Prescribing
1. QUESTION: What are the four key components of pharmacokinetics?
ANSWER: ✓ Absorption, Distribution, Metabolism, Excretion.
2. QUESTION: A 65-year-old patient with heart failure requires a medication. How
might their age-related decrease in renal function alter the drug's pharmacokinetics?
ANSWER: ✓ Reduced renal excretion may lead to drug accumulation, increasing the risk
of toxicity. Dosing intervals may need to be lengthened or doses reduced.
3. QUESTION: What is the "First Pass Effect" and how does it impact oral drug
administration?
ANSWER: ✓ It is the metabolism of a drug by the liver after absorption from the GI tract
and before it reaches systemic circulation. It can significantly reduce the bioavailability
of the drug.
4. QUESTION: Differentiate between a drug's mechanism of action and its therapeutic
effect.
ANSWER: ✓ The mechanism of action is the specific biochemical interaction through
which the drug produces its effect (e.g., blocking a receptor). The therapeutic effect is
the desired beneficial outcome (e.g., reduced blood pressure).
5. QUESTION: Why is the concept of "Half-life" critical in determining a dosing
schedule?
ANSWER: ✓ The half-life determines how long a drug remains active in the body. Drugs
with a short half-life require more frequent dosing to maintain therapeutic levels, while
those with a long half-life can be dosed less frequently.
, 6. QUESTION: What is the primary safety consideration when prescribing a drug with a
narrow therapeutic index?
ANSWER: ✓ There is a very small margin between the therapeutic dose and the toxic
dose. Serum drug level monitoring and close patient observation are often required.
7. QUESTION: Describe the role of Cytochrome P450 enzymes in drug metabolism and
provide one example of a drug interaction it can cause.
ANSWER: ✓ CYP450 enzymes are responsible for metabolizing many drugs. Example:
Fluconazole (an inhibitor of CYP3A4) can increase levels of simvastatin (metabolized by
CYP3A4), raising the risk of myopathy and rhabdomyolysis.
8. QUESTION: What is the Beers Criteria, and why is it important for a primary care
provider?
ANSWER: ✓ It is a list of medications that are potentially inappropriate for use in older
adults due to increased risks of adverse effects. It is a key tool for improving medication
safety in the geriatric population.
9. QUESTION: In the context of prescribing, what does the acronym "TERM" stand for in
patient education?
ANSWER: ✓ Therapeutic goal, Effects (both desired and
adverse), Route/dosage/timing, Monitoring.
10. QUESTION: A patient's pharmacogenomic profile indicates they are a "poor
metabolizer" for a specific CYP450 enzyme. How would this influence your prescribing?
ANSWER: ✓ I would avoid drugs that are primarily metabolized by that enzyme or
choose an alternative. If no alternative exists, I would initiate therapy at a much lower
dose to prevent drug accumulation and toxicity.
Module 2: Autonomic & Cardiovascular Pharmacology
11. QUESTION: What is the first-line pharmacologic class for uncomplicated
hypertension in most patients, according to JNC 8 guidelines?
ANSWER: ✓ Thiazide diuretics, ACE inhibitors, Angiotensin II receptor blockers (ARBs),
or Calcium channel blockers.
12. QUESTION: A patient starting an ACE inhibitor (like lisinopril) should be monitored
for what two common side effects?
ANSWER: ✓ A persistent dry cough and hyperkalemia.
(2025/2026 Syllabus)
Disclaimer: This guide is a supplement to, not a replacement for, the textbook and
official course materials. Drug choices and dosages must be verified with current,
authoritative sources before clinical application.
Module 1: Foundations of Pharmacology & Prescribing
1. QUESTION: What are the four key components of pharmacokinetics?
ANSWER: ✓ Absorption, Distribution, Metabolism, Excretion.
2. QUESTION: A 65-year-old patient with heart failure requires a medication. How
might their age-related decrease in renal function alter the drug's pharmacokinetics?
ANSWER: ✓ Reduced renal excretion may lead to drug accumulation, increasing the risk
of toxicity. Dosing intervals may need to be lengthened or doses reduced.
3. QUESTION: What is the "First Pass Effect" and how does it impact oral drug
administration?
ANSWER: ✓ It is the metabolism of a drug by the liver after absorption from the GI tract
and before it reaches systemic circulation. It can significantly reduce the bioavailability
of the drug.
4. QUESTION: Differentiate between a drug's mechanism of action and its therapeutic
effect.
ANSWER: ✓ The mechanism of action is the specific biochemical interaction through
which the drug produces its effect (e.g., blocking a receptor). The therapeutic effect is
the desired beneficial outcome (e.g., reduced blood pressure).
5. QUESTION: Why is the concept of "Half-life" critical in determining a dosing
schedule?
ANSWER: ✓ The half-life determines how long a drug remains active in the body. Drugs
with a short half-life require more frequent dosing to maintain therapeutic levels, while
those with a long half-life can be dosed less frequently.
, 6. QUESTION: What is the primary safety consideration when prescribing a drug with a
narrow therapeutic index?
ANSWER: ✓ There is a very small margin between the therapeutic dose and the toxic
dose. Serum drug level monitoring and close patient observation are often required.
7. QUESTION: Describe the role of Cytochrome P450 enzymes in drug metabolism and
provide one example of a drug interaction it can cause.
ANSWER: ✓ CYP450 enzymes are responsible for metabolizing many drugs. Example:
Fluconazole (an inhibitor of CYP3A4) can increase levels of simvastatin (metabolized by
CYP3A4), raising the risk of myopathy and rhabdomyolysis.
8. QUESTION: What is the Beers Criteria, and why is it important for a primary care
provider?
ANSWER: ✓ It is a list of medications that are potentially inappropriate for use in older
adults due to increased risks of adverse effects. It is a key tool for improving medication
safety in the geriatric population.
9. QUESTION: In the context of prescribing, what does the acronym "TERM" stand for in
patient education?
ANSWER: ✓ Therapeutic goal, Effects (both desired and
adverse), Route/dosage/timing, Monitoring.
10. QUESTION: A patient's pharmacogenomic profile indicates they are a "poor
metabolizer" for a specific CYP450 enzyme. How would this influence your prescribing?
ANSWER: ✓ I would avoid drugs that are primarily metabolized by that enzyme or
choose an alternative. If no alternative exists, I would initiate therapy at a much lower
dose to prevent drug accumulation and toxicity.
Module 2: Autonomic & Cardiovascular Pharmacology
11. QUESTION: What is the first-line pharmacologic class for uncomplicated
hypertension in most patients, according to JNC 8 guidelines?
ANSWER: ✓ Thiazide diuretics, ACE inhibitors, Angiotensin II receptor blockers (ARBs),
or Calcium channel blockers.
12. QUESTION: A patient starting an ACE inhibitor (like lisinopril) should be monitored
for what two common side effects?
ANSWER: ✓ A persistent dry cough and hyperkalemia.
